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SUMMARY
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While advances in patient care and immunosuppressive pharmacotherapies have increased the
lifespan of heart allograft recipients, there are still significant comorbidities post-transplantation
and 5-year survival rates are still significant, at approximately 70%. The last decade has seen
massive strides in genomics and other omics fields, including transcriptomics, with many of these
advances now starting to impact heart transplant clinical care. This review summarizes a number
of the key advances in genomics which are relevant for heart transplant outcomes, and we
highlight the translational potential that such knowledge may bring to patient care within the next
decade.
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Introduction

Author Manuscript

Heart transplantation is often the only available treatment for patients with significant
congenital cardiac disease and/or end-stage heart failure [1,2]. Advances in
immunosuppressive therapies (IST), surgical techniques, and preoperative and postoperative
patient management have yielded substantial gains in short- and long-term post-transplant
outcomes over the last few decades [2]. Despite these advances, the 5-year heart allograft
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survival rates are ~71%, because of an interplay of immune related as well as nonimmune
comorbidities including hypertension, diabetes, dyslipidemia, a range of coronary diseases,
infection, renal insufficiency, and malignancies [3]. Acute rejection (AR) is most likely to
occur in the first three to twelve months post-transplant, with at least one rejection episode
occurring in upwards of 50% of cardiac transplant recipients. AR remains a frequent and
life-threatening complication increasing the risk of acute and downstream graft damage [1,4]
and greatly impacts the progression of chronic allograft vasculopathy (CAV), which is the
leading cause of diminished cardiac allograft survival [1]. Acute and chronic rejection
pathogeneses are complex, affected by many established factors such as human leukocyte
antigen (HLA) mismatches, immunosuppression regimens, compliance, and recipient age
[5].

Author Manuscript
Author Manuscript

Patients who receive renal allograft from HLA-identical donors can undergo acute or chronic
rejection, indicating a role for non-HLA factors in alloimmunity [6]. Large-scale
retrospective analyses of 10-year national registry data show that ~18% of allograft failures
are attributable to donor–recipient (D-R) HLA genetic factors, with 38% of the failures
reported to be caused by immunological reactions against non-HLA factors (as observed in
HLA-identical sibling grafts) [7]. There is a clear lack of knowledge of the genetic
underpinnings of allograft rejection and other complications of transplantation, and
understanding these processes may advance clinical management of individual heart
transplant recipients and impact short- and long-term allograft survival. While assessment of
HLA compatibility for heart transplant donor–recipient (D-R) selection is an important
factor for graft survival outcomes, it is not always predicated in all transplant centers,
because of limited pools of available organs and time constraints with recovery of thoracic
organs from deceased donors, but it is becoming increasingly implemented and standardized
across national programs [8].

Author Manuscript

The last decade has seen staggering progress in genomic and other omic technologies, and
their application in the Mendelian and complex disease arena. Since the initial draft
sequences of the first human genomes nearly 15 years ago, genetic single nucleotide
polymorphism (SNP) maps have been generated across the major human populations using
genome-wide genotyping panels of typically >500 000 to several million SNP markers. This
has facilitated the advent of genome-wide association studies (GWAS) which have led to the
elucidation of robust genetic associations for the vast majority of polygenic traits and
diseases with heritable components [9]. Subsequent advances in sequencing chemistries and
advanced engineering allowed the capture and sequencing of the known gene-coding
regions, termed whole-exome sequencing (WES) as well as whole-genome sequencing
(WGS). These processes have become more affordable in the last 2–3 years, and sequencing
of thousands of large reference populations has facilitated characterization of common and
rarer genetic variants [10], leading to the broad observation that two unrelated human
genomes differ by ~3.5 million to 10 million polymorphisms, depending on their respective
ancestral backgrounds. WGS of human populations also shows that an average genome
contains ~100 genuine loss-of-function (LoF) variants (defined as variants ablating all of
part of a gene product/function), with ~20 genes having LoFs in both copies [11]. Two copy
LoFs may cause graft rejection through the LoF gene product in the donor being treated as
an allogenic epitope [12–16]. Additional sources of neo-antigens include stop-loss mutations
Transpl Int. Author manuscript; available in PMC 2018 June 06.
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where the conventional stop codon is disrupted resulting in novel amino acids being
synthesized. Indeed, recent WES in >15 500 human protein-coding genes in >2 000
individuals of diverse ancestry identified more than 500 000 variants < 1% frequency with
an average of >13 500 low-frequency variants observed per individual, of which ~2% was
predicted to impact the function of > 300 genes, per genome assessed [11,17]. While it is
clear that a broad spectrum of genetic differences could represent significant reservoirs of
potential mHA differences which could potentially contribute to allogenicity and thus acute
rejection pathology, there have been limited efforts to date to look at the global mismatches
of amino acids between donors and recipients.

Author Manuscript

Studies of genetic polymorphisms in association studies using large well-characterized heart
transplant cohorts are currently lacking. We also discuss how advances in genome-wide
tools can be used to unveil sources of potential alloimmunity in, and beyond, conventional
HLA regions, and we outline a number of key genomic studies in pharmacological genes
(pharmacogenes) relevant in the transplant setting and where such knowledge may begin to
be implemented in broader clinical care in pre- and postcardiac transplant clinical
management. We discuss a recently formed transplant genomic consortium whose aims are
to discover and validate genome-wide associations for a number of complications posttransplant. We also outline recent advances in the development of molecular characterization
of allograft biopsies, as well as noninvasive or minimally invasive biofluids, for diagnoses
and prognostication of acute rejection. This is particularly relevant in the post-transplant
cardiac allograft setting where standard-of-care in many post-transplant clinics necessitates
frequent highly invasive protocol biopsies to assess rejection at a histopathology level.

Genetics and genome-wide studies in heart transplantation
Author Manuscript

The human major histocompatibility complex (MHC) and natural killer cell
immunoglobulin-like receptor (KIR) regions
The Human MHC region, located on the short arm of chromosome 6, comprising ~200
coding genes including the HLA Class I (HLA-A,-B, and -C), II (HLA-DPA1,-DPB1,DQA1,-DQB1,-DRA, and -DRB1), and III gene families, with HLA Class I and II exons
being the most polymorphic regions observed across the human genome. The MHC region
consistently shows the strongest associations for a wide range of diseases and phenotypes
[9], and associations of HLA polymorphisms with transplant outcomes are well-established
[18–21]. HLA Class I/II molecules are key proteins responsible for the presentation of
endogenously and exogenously derived peptides to T cells.

Author Manuscript

HLA Class I and Class II matching is well established in graft outcomes in renal and
hematopoietic cell transplantation (HCT). While there is a clear role for HLA compatibility
in transplantation outcomes of other solid organs, currently, the use of HLA matching is not
performed in all heart transplant regions, because oflimited availability of organs and time
constraints with HLA typing and recovery of organs. De novo antibody production has a
clear impact on cardiac allograft recipient survival (Hazard Ratio > 3), with HLA Class II
DQ-specific donor-specific antibody (DSA) being observed with poorer outcomes [22,23].
There is also an increasing body of evidence that nonclassical HLA molecules, such as
HLA-G, also impact transplant outcomes [24,25,26]. There is a major need for more
Transpl Int. Author manuscript; available in PMC 2018 June 06.
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comprehensive catalogs of polymorphisms across the HLA Class I, II, and wider MHC
regions such as the Immuno Polymorphism Database (IPD) which contains a wealth of HLA
alleles [27], although there is still a limited amount of HLA datasets from non-EA
populations. There is an ever-growing body of clinical data showing that epitope-based HLA
matching is superior to conventional HLA antigen matching for a range of post-transplant
clinical outcomes, and it is likely that these approaches will become a major consideration in
clinical D-R matching in the next few years [28,29].

Author Manuscript
Author Manuscript

The KIR region, the second most polymorphic region in the genome after the MHC, is
comprised of a family of 13 genes on chromosome 19 [30]. KIRs play essential roles in
educating and regulating the ability of NK cells to sense and respond to HLA Class I surface
expression and have been shown to have critical roles in human health and are implicated in
multiple immune-related diseases [31–33], and clinical studies show associations of
combinatorial diversity of KIR and HLA alleles with multiple diseases, including infections
and autoimmune disorders [18,20,21]. KIR/HLA Class I incompatibility exemplifies how
interactions may negatively impact histocompatibility and while the impact of KIR-HLA
mismatch in transplantation is controversial [21,34], recent studies do show evidence of KIR
genotype associations with kidney and HCT transplant-related outcomes [35–37], although
no well-powered studies to date have been performed in heart transplantation. There is some
recent intriguing data that indicate that surveillance of CD28 and KIR2D receptor expression
on T lymphocytes correlate with immune status of both heart and liver recipients [38]. As
KIR and HLA Class I genes are located on different chromosomes, the statistical power to
assess potential SNP–SNP interactions becomes very constrained. Where HLA and KIR
have not been directly sequenced, it is possible to infer or “impute” HLA and KIR amino
acid status from GWAS, WES, and WGS datasets using a number of different open-source
algorithms [39–42]. Such approaches may add significant insight into additional HLA/KIR
associations with transplant outcome particularly where samples were not typed at high
resolution or at all, which is the case for most liver transplant centers.
Genetic association studies in transplantation across the rest of the human genome

Author Manuscript

It is also becoming increasingly evident that non-HLA variants, often termed minor
histocompatibility antigen (mHA), impact rejection risk in transplantation [6,7,43,44]. In
females receiving a male kidney allografts, worst survival outcomes were observed versus
all other gender–gender D-R combinations [45]. This has been attributed in part to the H-Y
antigen, against the Y-chromosome male-enhanced antigen MEA1 gene which has been
associated with acute renal rejection [46]. D-R genetic differences in mHA across the entire
human genome have yet to be investigated at large-scale in the solid organ transplant setting
let alone in the cardiac transplant setting.
Association studies of polymorphisms in a priori candidate genes are notorious for
publication bias and spurious and inconsistent results, and there are often confounding issues
across sites such as adjustment for ancestry of the study participants [47]. The majority of
genetic studies in transplantation outcomes published to date have mostly been limited to a
priori candidate gene regions, suffer from small study sample sizes, and lack of replication
in independent studies. The clinical and demographic covariates of recipient and donors in
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transplantation are extremely complex relative to most common genetic disease studies, and
it is thus not surprising that apart from pharmacogenetic/genomic studies with large effect
sizes in genes known to impact that replication of initial findings is limited.

Author Manuscript
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To date, only a handful of solid organ transplant GWA studies have been performed in
modest numbers of patients and have focused mostly on renal transplantation (reviewed in
an accompanying review article in this edition [48]) with very few significant findings. The
only GWA study using heart transplant subjects was performed in relation to skin cancer
outcomes [49]. There have been several dozen candidate genes studies in the heart transplant
field, but only two studies used over 500 DNA samples. Four beta-adrenergic receptor
(βAR) polymorphisms were screened by Khush et al in donor hearts to assess left
ventricular (LV) dysfunction after brain death in 1 043 heart transplant donors from 2001 to
2006 [50]. The β2AR-46 SNP was significantly associated with LV systolic dysfunction in
multivariable regression analyses, with carriage of the less common variants significantly
impacting LV ejection fraction. The β1AR1165 and β2AR46 SNPs were associated with
increased inotropic dopamine requirement during procurement of the allograft (OR of 2.6
for requiring >10 µg/kg/min of dopamine compared to those with the homozygous wild-type
genotypes). Gallardo and colleagues examined the impact of common mitochondrial
variants and contiguous stretches of variants or “haplotypes,” on end-stage heart failure in
patients undergoing heart transplantation, in relation to CAV and graft survival, in 450
recipients, 248 donors, and 206 healthy controls [51]. Carriage of mitochondrial haplogroup
H was significantly higher in recipients versus controls [OR: 1.86 (95% CI: 1.27–2.74), P =
0.014, and in recipients versus donors (OR: 1.47 [95% CI: 0.99–2.19), P = 0.032]) after
adjustment for age and sex. In CAV patients versus non-CAV patients, the haplogroup Uk
was observed to be significantly more frequent (OR: 4.1 [95% CI: 1.51–11.42], P = 0.042).
Additionally, haplogroups in the heart donor were observed to have no impact on the
morbidity or graft survival after heart transplantation.

Author Manuscript

There is an ever-growing catalog of specific variants that impact drug uptake, metabolism,
clearance, efficacy, and severe adverse events [52,53]. Large consortia, such as the Clinical
Pharmacogenetics Implementation Consortium (CPIC) [54] and the Pharmacogenomics
Research Network (PGRN) [53], are making significant advances in discovery and
systematic documentation of a number of these key pharmacogenes and specific
polymorphisms of major clinical value. Transplant patients are exposed to large number of
pharmacotherapies over extensive periods of time including, immunosuppressants, inotropic,
anti-hypertensive, and dyslipidemia agents as well as anti-fungal, anti-viral and antibiotic
treatments, and chemotherapies. Table 1 outlines the most commonly prescribed drugs preand postcardiac transplant, and known genes and variants which impact patient responses to
these drugs. Table 1 also outlines the current CPIC and PGRN guidelines along with the
current FDA recommendation for patient monitoring/testing for these drugs. There has been
much focus to date on the pharmacogenetics/pharmacogenomics of tacrolimus, the most
commonly used immunosuppressant, as there is high interindividual variability in dosing
required to reach, and to maintain, optimal therapeutic trough levels [55]. The narrow
therapeutic range requires close monitoring of plasma drug concentrations especially during
the initial period post-transplant. Trying to balance avoidance of overimmunosuppression,
which can lead to nephrotoxicity and increased risks of opportunistic infections, against
Transpl Int. Author manuscript; available in PMC 2018 June 06.
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undersuppression of the allograft recipient, which can lead to increased risk of acute
rejection, can be challenging in many patients [56]. While gender, age, BMI, type 2 diabetes
status and exposure to calcium channel blockers influence tacrolimus blood levels and
clearance, an intronic LoF variant CYP3A5*3 (rs776746), in cytochrome P450 3A5
(CYP3A5), the main enzyme that metabolized tacrolimus, explains ~45% of drug level and
30% of clearance. CYP3A5*1 classically referred to a functional gene copy of CYP3A5, but
without ascertainment of all variants in the gene-coding regions, as well as in the intronic
and untranslated regions, then a “CYP3A5*1 functional gene status” cannot truly be derived.
Additional variants, including CYP3A5 *2, *5, *6, *7, *10, and CYP3A4 22*, cause LoF or
reduced expression of these key enzymes and have been found to explain an additional 20%
of the genetic variance in tacrolimus blood levels. The allele frequency of CYP3A5*3 is
~82–95% in European ancestral populations and ranges from 33% in African to 75–85% in
Asian and 75% in Mexican populations [57]. Higher carriage of LoF SNPs in CYP3A5, as
observed in European, Hispanic, and Asian populations, invariably requires that less
tacrolimus dosing be administered to reach and maintain optimal trough level, and indeed,
less nephrotoxicity and side effects are observed because of lower cumulative tacrolimus
exposure. African Americans are known to have higher rates of rejection following kidney
transplantation, which may be caused in part from failure to reach therapeutic
immunosuppression dosing of tacrolimus [58,59].

Author Manuscript

Ancestry has also been shown to play an important role in heart transplantation. A
retrospective analysis of over 20 000 adult heart allograft recipients transplanted from 1997
through 2007 assessed the impact of D-R race-matching, on mortality using 23 variables and
D-R interaction terms. African Americans recipients were shown to have an 11.4% absolute
decrease in 10-year survival and a 46% proportional increase in the risk of cumulative
mortality (HR, 1.46; 95% CI, 1.24 to 1.72; P < 0.001) versus European recipients [60].
Decreased survival in recipients from African American allograft donors or any other racial
groups was not observed to be improved with race-matched transplantation in this study.
African Americans have been shown to exhibit poorer transplant outcomes versus those of
European ancestry, even after adjusting for clinical and socioeconomic covariates [61].
Using United Network for Organ Sharing (UNOS) registry data for 14 265 heart transplant
patients, a 13-point risk score incorporating age, race, sex, HLA matching showed high
predictive ability for clinically important rejection episodes within 1 year [62]. Race was
observed to impact one-year rejection rates; when excluding individuals of European
ancestry, individuals of non-European ancestry had comparable rejection rates, with the
exception of cardiac allograft recipients of Asian descent, who had reduced rates of
rejection.

Author Manuscript

The international genetics & translational research in transplantation network
(iGeneTRAiN)
Large well-characterized numbers of genome-wide datasets are needed for D-R pairs or for
recipient-only samples, to accrue sufficient numbers of transplant-related phenotypes/events
[63]. This was one of the main considerations for establishing iGeneTRAiN, whose initial
aims are to generate and harmonize genome-wide genotyping and phenotypic datasets across
transethnic heart, kidney, liver, and lung transplant studies, and integrating analyses and risk
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models to increased statistical power to detect transplant-related outcomes ([63] and
www.igenetrain.org).
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iGeneTRAiN has now aggregated GWAS and phenotypic datasets from >48 000 DNAs from
transplant subjects and controls (with >12 000 D-R pairs), collected from 1989 to present,
including >1 800 heart transplant recipients and >1 000 of their respective deceased donors
[49,63–67]. A dedicated GWAS array, the “TxArray,” with 780 000 markers, designed for
the transplant community by iGeneTRAiN, provides robust genome-wide coverage using
conventional genome-wide mapping content, but with dense coverage of variants in key
transplant-related regions, such as MHC, KIR and is enriched for recent pharmacogenomic
and CKD related-findings [27]. Furthermore, a deep collation of all published cardiac
allograft genetic association studies (and all other solid organs) up to 2015 was performed,
and probes for these genetic variants were directly captured on the array to allow for metaanalyses with previous publications. A dedicated pipeline for quality control and processing
of the GWAS data has been developed (see Fig. 1) for the transplant community. A number
of clinically relevant transplant outcomes, including graft and patient survival, acute and
chronic rejection, new-onset of diabetes after transplant (NODAT), cause of transplant, and
various malignancies, are being investigated using recipient-only, donor-only, and various DR models.

Diagnostics & prognostication biomarker studies of post-transplant
complications

Author Manuscript

Most transplant centers currently diagnose cardiac allograft rejection through histological
evaluation of endomyocardial biopsy (EMB) from surveillance standard-of-care visits or
from “for-cause” biopsies after the onset of clinically observed allograft dysfunction. EMBs
are costly, highly invasive and are subject to interobserver variability and sampling errors at
the histopathology level [68]. Furthermore, surveillance biopsies may detect allograft
rejection after irreversible damage has already occurred. Early identification of biological
markers of subclinical allograft rejection and/or injury using highly sensitive and specific
assays may allow more timely intervention to preserve graft function and thus increase
allograft lifespan. The development of diagnostic and prognostic biomarkers of allograft
dysfunction has been a major endeavor of many groups over the last two decades, with most
of the focus being on the transcriptome (mRNA and miRNA studies) and donor-derived cellfree DNA (dd-cfDNA) [69].
Messenger RNA (mRNA) studies

Author Manuscript

The Cardiac Allograft Rejection Gene Expression Observational (CARGO) study, which
began in 2001 [70], collected blood and EMBs from the corresponding timepoints of heart
allograft recipients across eight sites and identified altered expression of 11 genes which
discriminates acute cellular rejection (ACR) from immunologically quiescence timepoints.
The CARGO investigators also developed an expression-based algorithm with a score from
0 to 40, where higher scores (34 or higher) are indicative of an acute rejection episode. This
assay was developed into an FDA approved in vitro diagnostic (IVD) and is available for
clinical use in stable heart allograft recipients. A number of additional studies including the
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Invasive Monitoring Attenuation through Gene Expression (IMAGE) Study compared
AlloMap to protocol EMB as the primary means of ACR surveillance assessing primary
outcomes of first rejection episodes with hemodynamic compromise allograft dysfunction,
retransplantation, or death [71]. The IMAGE study observed similar outcomes in the
AlloMap-alone versus EMB groups for primary outcome incidences (14.5% vs. 15.3%). The
CARGO II study found that the negative predictive value (NPV) for a graft failure,
retransplantation, or death was 97% where patients had an AlloMap score variability (AMV)
of 0.6 (defined as the standard deviation of four Allo-Map scores collected at least 315 days
post-transplantation with a 95% CI of 91.4–100) [72]. As of the middle of 2017, over 100
000 blood samples from heart transplant recipients had been subjected to AlloMap assays.

Author Manuscript
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A recent cardiac allograft rejection mRNA diagnostic study examined EMBs from four
French transplant centers for antibody-mediated rejection (AbMR) (n = 55) with a control
group of 55 biopsies without AbMR, and a Canadian validation cohort of 27 AbMR cases
and 71 non-AbMR controls using ISHLT 2013 histopathology grading [73]. Genome-wide
expression microarrays were used to molecularly characterize the entire 240 biopsies and
demonstrated molecular pathways within the AbMR samples characterized by endothelial
activation with microcirculatory inflammation from monocytes–macrophages and NK cells.
They also showed changes in endothelial, angiogenesis, and NK cell mRNA expression
profiles, including CD16A signaling and mRNAs, influenced by interferon-γ. Panels of
AbMR-related transcripts demonstrated decent discrimination for AbMR biopsies versus
non-AbMR: NK-related (AUC = 0.87), endothelial activation-related (AUC = 0.80),
macrophage-related (AUC = 0.86), and interferon-γ-related (AUC = 0.84) (with P < 0.0001
for all four sets). These four gene panels showed increased expression with increasing
ISHLT grading of AbMR pathology (P < 0.001) and association with DSA levels. These
samples are part of a major international effort called Molecular Microscope Diagnostic
System (MMDx) examining AbMR and T-cell mediated rejection (TCMR) and other posttransplant compilations across a range of solid organ allograft biopsies. These are, and will
undoubtedly continue to be, a significant reference resource for characterization of subtypes
of rejection as well as other complications of rejection such as CAV. Indeed, subsets of the
expression classifiers of AbMR in the study showed association with CAV [73]. Array-based
expression platforms have a number of limitations compared to more recent methods which
include sequencing RNA transcripts (RNA-Seq). When comparing human T-cell activation
using RNA-Seq against microarray-based-expression, RNA-Seq demonstrates superiority in
dynamic range, as well as for detection of low abundance transcripts, and differentially
expressed mRNA isoforms [74].

Author Manuscript

MicroRNA (miRNA) studies
Noncoding RNAs include microRNAs (miRNAs), which are typically 22 nucleotides in
length, are potent regulators of transcriptional and post-transcriptional gene expression.
They have been shown to disperse into the periphery circulatory system from cells within
solid organs, and their small sizes make them less susceptible to RNase enzymatic
degradation. Furthermore, they are generally stable in blood at room temperature for up to
48 hours, and thus, they are an attractive target to assess patterns of injury or recovery in
disease processes [75]. In one of the most recent and largest cardiac allograft miRNA study
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conducted to date, EMBs from 113 heart transplant recipients from four French transplant
sites (discovery component n = 60, validation cohort, n = 53) [76] were screened for miRNA
levels. In the discovery arm, miRNA expression was compared between EMBs and sera
from patients with acute biopsy-proven allograft rejection (n = 30) versus controls subjects
without rejection (n = 30). Seven miRNAs were observed to be differentially expressed
between allograft rejection timepoints versus nonrejection biopsies (P < 0.0001). Of these
seven miRNAs, four were observed to be detectable and exhibited differential expression in
sera. The ROC analyses showed that these four circulating miRNAs strongly discriminated
allograft rejection versus those without rejection (all had AUC ranging from >0.93 to >0.99
with P < 0.0001), and these signals were confirmed with an additional replication set of
cardiac allograft patient sample sets. Furthermore, the discrimination capability of the four
miRNAs remained significant when stratified by TCMR versus AbMR diagnoses, and time
post-transplant.

Author Manuscript

Cell-free circulating DNA (cfDNA) studies
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Stemming from seminal noninvasive prenatal diagnoses (NIPDs) research which assesses
fetal DNA in maternal blood, the cfDNA approaches in transplantation take advantage of
donor-derived circulating cfDNA (dd-cfDNA) which has been shown to increase in ratio
when compared with recipient DNA after necrosis/apoptosis of donor allograft cells/tissue
[77]. Panels of several hundred SNPs across the genome, whose frequencies are high in the
most common human populations, can be used to discriminate donor and recipient DNA
ratios in the blood of kidney, lung, and heart recipients. The dd-cfDNA method was first
successfully applied in heart transplantation in a retrospective study where increased levels
of dd-cfDNA were shown to correlate with ACR episodes using EMB as the reference
pathological standard [78]. The clinical utility of dd-cfDNA in monitoring acute rejection
was subsequently tested in a prospective heart transplant recipient study [79]. dd-cfDNA
was shown to be highly elevated from day 1 post-transplant (indicative of early ischemia–
reperfusion injury postsurgery), followed by a quick decline to <0.1% within a week, and
remained low until a rejection event. The performance of dd-cfDNA in distinguishing
ISHLT Grade 2 or 3 rejections from immunological quiescence had an observed AUC of
0.83, with a sensitivity of 58% and a specificity of 93%. The authors also outlined the use of
dd-cfDNA monitoring as a prognostic monitoring assay for rejection as levels of dd-cfDNA
were observed to be significantly elevated weeks to months preceding a rejection episode.
As dd-cfDNA can be assessed at defined periods post-transplant, in a minimally invasive
manner, and as it is essentially a quantitative read-out of donor versus recipient cfDNA, then
it can also be used in a prognostic manner to monitor heart allograft status. Cell-specific ddcfDNA approaches, using methylation and/or histone mapping, to identify the cell(s) or
tissue of origin of the cfDNA, are now emerging as powerful tools to delineate the
underlying cause of increased dd-cfDNA [80,81].

Discussion and future directions
To date, genetic association studies in heart transplant studies have mostly been limited to
the HLA and pharmacogenomic setting, although a number of large-scale GWA studies
including iGeneTRAiN are now underway with GWAS from >1 800 heart allograft
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recipients and >1 000 donors. There are still significant challenges that have to be overcome
though and greater numbers of samples are needed, as well as collaboration between sites
for more comprehensive phenotype harmonization, as adjusting for clinical and
demographic recipient and donor covariates across sites can be very challenging. A wealth
of existing DNA already exists for donor and recipient DNA samples from organ
procurement organizations (OPOs) and HLA reference laboratories. With appropriate
regulatory approval, these D-R genomic and outcome datasets can be linked with medical
records (EMRs) and national-level databases such as the Scientific Registry of Transplant
Recipients (SRTR), the most powerful registry in the United States, for assessment of longterm post-transplant outcomes [82]. Knowledge gained from how MHC, KIR, and mHA
variants impact outcomes will facilitate greater insight into the potential biology of genomic
incompatibility of D-R pairings, which may lead to better patient care through more regular
monitoring of recipients paired with a higher genetic-risk donor. With the increased use of
LVADs and rapid-HLA genotyping, more appropriate D-R matching prior to transplantation
may be possible based on MHC/HLA, KIR, and mHA genotype combinations.
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In the last decade, there have been significant advances in the development of molecular
tools for the diagnoses and prognoses of acute and chronic rejection, as well as other
complications post-transplant. While there are better international classifications of acute
rejection, there are still significant issues with histopathology grading, and there is an
increasingly clear case for molecular characterization of the EMB for diagnoses and
prognostication of various outcomes. Furthermore, blood samples from the same timepoints
will likely have value for immune surveillance in a minimally invasive manner as we move
toward miRNA, mRNA, and dd-cfDNA laboratory developed tests (LDT) and IVD assays
with better sensitivity and specificity [71,83–85]. Ultimately, with robust enough
biomarkers, such approaches could lead to personalization of immunosuppression therapy to
limit side effect, but great caution is needed in this area [86].

Author Manuscript

Comparing biomarker signatures across different solid organ allograft studies is also an area
of major value as while there are clearly organ-specific signals in post-transplant outcomes,
there is also biological overlap in a number of processes related to rejection and other posttransplant complications across all solid organ transplants. Levels of miR-21 were observed
to be associated with AR, fibrosis, and CAV in heart recipients [76,87] but were also
associated with ischemia–reperfusion injury, fibrosis AbMR, and other complications in
kidney [88–91] and with graft dysfunction in lung allografts [92]. Furthermore, downstream
miRNAs derived from miR-142 (miR-142-5p and miR-142-3p) are associated with AR,
chronic rejection, and/or fibrosis across all four major solid organ transplantations [92–96].
Levels of miR-223p-3p and miR-93-5p were shown to be present in CKD stages [97], which
may also have broad utility for routine monitoring of kidney function in cardiac and other
allograft patients especially when combined with miRNAs that are known to have clinical
utility in post-transplant surveillance. Furthermore, assessment of 10 genes expressed in
blood that are diagnostic of kidney acute rejection was shown to have utility in a study of
250 blood samples from heart transplant recipients with and without acute rejection,
indicating common pathways of immune activation [65].
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Genomic and other omic applications will undoubtedly start to play a more significant role
in the personalization of patient management in the heart transplant setting. Ascertaining the
genetic underpinnings of various types of cardiac allograft rejection and complications posttransplantation will yield significant advances in our understanding of fundamental
molecular processes involved in such processes. Identification of potential new genomic
biomarkers for diagnoses and prognostication of post-transplant outcomes, as well as risk
stratification of transplant patients, is also likely to result from such studies.
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Figure 1.
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iGeneTRAiN Genome-wide association study analyses (GWAS) pipelines. The genomewide association study analyses (GWAS) for The International Genetics & Translational
Research in Transplantation Network (iGeneTRAiN) is illustrated from assessment of the
DNA quality for the different studies, through to the wet-laboratory processing of the
genome-wide genotyping plates to generate several hundreds of thousands of SNP/SNV
genotype calls. The pipelines for genome-wide imputation (IMPUTE2 and ShapeIT) HLA
(SNP2HLA, HLA*IMP) and KIR (KIR*IMP) are generated and phased. The loss-offunction (LoF) pipeline using VEP and LOFTEE utilizes the phased imputed GWAS data
(typically 15 million variants) and copy number variant (CNV) is generated from the raw
image files using standard Affymetrix pipelines or PennCNV [98]. The donor–recipient
interaction analyses utilized the imputed LoF and CNV datasets, using ancestry data derived
from the GWAS data and other means including genome-wide amino acid mismatches.
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Finally, the phenotypes and covariates of interest are integrated with the various GWASderived datasets primarily using PLINK [99].
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Belinostat
Cisplatin
Irinotecan
Nilotinib
Sunitinib

C/D

C

A, D, D

D, D, D, C/D,
D

B

D, D, D, D

A, D, D, D,
C/D, C

D

D, A

D, A, D

D, A

C/D

C, A

A

B

B

B

CPIC level (s)

23988873 (DPYD)

24096968 (IFNL3)

24096968 (IFNL4)

26417955 (UGT1A1)

22378157;24561393

CPIC publications (PMID)

The major classes of drugs prescribed to patients post-transplantation are shown along with specific drugs and the genes of known interaction.
For the Pharmacogenomics Knowledgebase (PharmGKB), the following describes the different degrees of evidence: Level 1A: clinical annotation for a variant–drug combination in a Clinical
Pharmacogenetics Implementation Consortium (CPIC) or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system; Level 1B: clinical annotation for a
variant–drug combination where the preponderance of evidence shows an association. The association must be replicated in >1 cohort with significant P-values, and preferably with a strong effect size;
Level 2A: clinical annotation for a variant–drug combination that qualifies for level 2B where the variant is within a Very Important Pharmacogene (VIP) as defined by PharmGKB. Variants in level 2A are
in known pharmacogenes, so functional significance is more likely. Level 2B: clinical annotation for a variant–drug combination with moderate evidence of an association. The association must be
replicated, but there may be smaller studies where statistical significance is not shown, and/or the effect size may be small; Level 3: annotation for a variant–drug combination based on a single significant
(but not yet replicated), or annotation for a variant–drug combination evaluated in multiple studies but lacking clear evidence of an association; Level 4: annotation based on a case report, nonsignificant
study or in vitro, molecular or functional assay evidence only.
For the CPIC Grading: Level 1 indicates that the evidence includes consistent results from well-designed and well-conducted studies; Level 2 indicates that the evidence is sufficient to determine the effects,
but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, by the inability to generalize to routine practice or by the indirect nature of the evidence; Level 3:
the evidence is insufficient to assess the effects on health outcomes because of the limited number of studies, insufficient power of the studies, or important flaws in the study design or in the way in which
they were conducted. A three-tier rating scheme is used for evaluating the strength of the recommendation where: A is a strong recommendation for the statement, B is a moderate recommendation for the
statement, and where C is an optional recommendation for the statement.

2B

3

3

UGT1A1

Anthracycline

Chemotherapy (other)
Actionable PGx

2B, 2B, 2A, 2B

CBR3, SLC28A3, NQO1,
HAS3

Fluorouracil

Actionable PGx (DPYD)

2B

24096968 (IFNL3)

VDR, IFNL3

Ribavirin

2A, 1A

Actionable PGx (IFNL3)

IFNL4, IFNL3, VDR

Peginterferon alfa-2b

1A, 1A, 2A

2B, 1A

Testing required

1A

Actionable PGx

HLA-B

Sulfadiazine

3

G6PD

Actionable PGx

G6PD

Norfloxacin

Abacavir

Actionable PGx

G6PD

Nitrofurantoin

PharmGKB level
of evidence

Chemotherapy (skin cancer)

Anti-Viral

FDA Label for PGx testing

Author Manuscript
Gene(s)

Author Manuscript

Drug

Author Manuscript

Drug class(es)
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